Erector Spinae Catheter for Open Heart Surgery (ESPADULT2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03901612 |
|
Recruitment Status :
Recruiting
First Posted : April 3, 2019
Last Update Posted : September 22, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Fast track to Extubation after cardiothoracic surgery is becoming more common after a number of reports showing it is safe and effective. However, It has introduced new challenges to pain control. Intubated patients require larger doses of opioids and benzodiazepines for comfort. In patients who are awake and spontaneously breathing, pain and agitation cannot be treated with lower doses.
Some centers still administer continuous infusions of opioid and benzodiazepines to extubated patients. These infusions may not be necessary and may even be harmful.
The recent pilot study (In press in Journal of cardio thoracic vascular anesthesia ) in our Vinmec hospitals performing open heart surgeries of peri-operative regional analgesia by Continuous Bilateral Erector Spinae Plane Blocks in adult showed that the pain relief was efficient and the requirement for opioids was zero in post-operative period.
It confirmed that the impact of regional anesthesia techniques on main procedure-specific postoperative outcomes is very important in opioids decreased use in the context of fast-track programs that are fully suggested after cardiac surgery.
In April 2017 we introduced the technique of ESP block for open heart surgeries in Adults and in pediatric. At the beginning we performed single shot block and the patients still needed during around 30 to 40 hours small doses of opioids to release their pain according to the evaluation by Comfort-B,FLACC VAS Scales. Since we are performing continuous peri-operative regional analgesia by Bilateral ESP catheters the requirement for additional opioids to release the pain is zero based on our practice of 480 ESP catheters for open heart surgeries.
We would like to compare the 2 analgesic techniques and analyze the post operative opioid consumption, the quality of recovery and the quality of life after the surgery.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Post Operative Analgesia | Drug: Ropivacaine 0.2% Drug: saline 09% | Phase 4 |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Randomized Controlled double blind |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Solution infused prepared by a different team with a rescue envelop to open in case of incident |
| Primary Purpose: | Treatment |
| Official Title: | Evaluation of a Peri-Operative Continuous Bilateral Erector Spinae Plane (ESP) Continuous Catheter After Open Cardiac Surgery in Adults |
| Actual Study Start Date : | January 5, 2019 |
| Estimated Primary Completion Date : | November 22, 2020 |
| Estimated Study Completion Date : | December 30, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Saline solution
Post operative analgesia throw the thoracic Erector spinae catheter with saline solution and opioid rescue
|
Drug: saline 09%
Continuous post operative regional analgesia |
|
Experimental: Ropivacaine
Post operative analgesia throw the thoracic Erector spinae catheter with Ropivacaine 0.2% solution and opioid rescue
|
Drug: Ropivacaine 0.2%
Continuous post operative regional analgesia |
- Opioid consumption [ Time Frame: From extubation to 48 hours after end of surgery ]Morphine consumption in milligrams
- Quality of recovery after the surgery [ Time Frame: 48 hours after end of surgery ]Quality of post operative recovery using the table QOR15* from 0 to 15
- Quality of Life after the surgery [ Time Frame: 30 days after end of surgery ]Quality of post operative life using the table QOL36* from 0 to 36
- post operative pain [ Time Frame: every 6 hours during 48hours after the end of the surgery ]Level of pain at rest and at mobilization using Visual analogic scale
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- all patients having an elective open heart surgery
Exclusion Criteria:
- refusal of the patient allergy to local anesthetics instable patient
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03901612
| Contact: Philippe Macaire, MD | +84966103845 | ph.macaire@gmail.com | |
| Contact: Mai Hoang, bachelor | +8483453993 | v.maihn@vinmec.com |
| Vietnam | |
| VinMec INternational hospital | Recruiting |
| Ho Chi Minh City, Vietnam | |
| Contact: Nga Ho | |
| Study Chair: | sebastien bertin, md | VinMec HS |
| Responsible Party: | Vinmec Healthcare System |
| ClinicalTrials.gov Identifier: | NCT03901612 |
| Other Study ID Numbers: |
VINMECCP |
| First Posted: | April 3, 2019 Key Record Dates |
| Last Update Posted: | September 22, 2020 |
| Last Verified: | September 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Ropivacaine Anesthetics, Local Anesthetics Central Nervous System Depressants |
Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |

